CEO, Nodus Oncology
Nodus Oncology, a company in the DDR area building a portfolio of assets with proven clinical activity. Currently developing NO1, an oral CHK1 inhibitor going into the clinic in 2021. Other DDR assets are being acquired. A key focus is defining the most appropriate cancer populations to benefit from specific DDR modulators.